Seagen

Seagen, Inc. is a biotechnology company focused on the development and commercialization of targeted cancer therapies. Founded in 1993 and headquartered in Seattle, Washington, the company specializes in antibody-drug conjugates (ADCs), a novel class of medicines designed to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Seagen’s mission is to transform the treatment landscape for patients with cancer by advancing innovative therapies that improve outcomes and quality of life.

The company’s flagship product, **Polivy (polatuzumab vedotin)**, is an ADC approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Polivy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in 2019 and has since been studied in combination with other therapies to expand its potential applications. Seagen also has a robust pipeline of ADC candidates targeting various cancers, including breast, lung, and hematologic malignancies.

In addition to ADCs, Seagen explores other therapeutic modalities, such as bispecific antibodies and immune checkpoint inhibitors, to further enhance its cancer treatment portfolio. The company collaborates with global pharmaceutical partners, including Genentech (a Roche company), to co-develop and commercialize its products. Seagen has also expanded its research capabilities through strategic acquisitions, such as the 2020 purchase of **AstraZeneca’s oncology portfolio**, which included the ADC **Trodelvy (sacituzumab govitecan)**.

Seagen is publicly traded on the NASDAQ under the ticker symbol **SGEN** and is committed to advancing precision medicine through scientific innovation. The company emphasizes clinical trials, regulatory engagement, and patient-centric approaches to bring new treatments to market efficiently. As of recent years, Seagen has faced challenges in maintaining consistent revenue growth but remains a key player in the biotech industry’s push toward more targeted and effective cancer therapies.